Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15697950 | 1.00 | HTT (0.47) | HTTALDH1A1HCAR3HCAR2TDP1 | |
| SCHEMBL11196579 | 0.84 | ALDH1A1 (0.47) | HTTALDH1A1TDP1SMN1; SMN2TP53 | |
| SCHEMBL9004065 | 0.83 | CA2 (0.49) | ALDH1A1SMN1; SMN2TP53TSHRMAPT | |
| SCHEMBL2878630 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL8635820 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL4526295 | 0.83 | ALDH1A1 (0.50) | ALDH1A1TDP1SMN1; SMN2TSHRCYP3A4 | |
| SCHEMBL7358892 | 0.82 | ITGB3 (0.50) | ALDH1A1TDP1TP53TSHRMAPT | |
| SCHEMBL7358881 | 0.82 | ITGB3 (0.50) | ALDH1A1TDP1TP53TSHRMAPT | |
| SCHEMBL29659890 | 0.82 | KMT2A (0.50) | HTTALDH1A1SMN1; SMN2TP53MEN1 | |
| SCHEMBL11195208 | 0.82 | HTT (0.45) | HTTALDH1A1TDP1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| US-6197820-B1 | METABOTROPIC GLUTAMATE RECEPTOR AGONIST/ANTAGONIST (S)-4-CARBOXYPHENYLGLYCINE (S-4CPG), POTENTLY AND SELECTIVELY INHIBITED GLUTAMATE RELEASE FROM GLIOMA CELLS AND THEREBY PREVENTED NEUROTOXICITY, INHIBIT RELEASE OF TOXIC LEVELS OF | UAB RESEARCH FOUNDATION | 2001-03-06 | — | — | US | claimed |
| WO-2000062771-A1 | USES OF PHENYLGLYCINE DERIVATIVES | THE UAB RESEARCH FOUNDATION (US) | 2000-10-26 | — | — | WO | claimed |
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230038631-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-02-09 | — | — | US | disclosed |
| US-20210251928-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIVERSITY | 2021-08-19 | — | — | US | disclosed |
| WO-2017142543-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2017-08-24 | — | — | WO | disclosed |
| US-9173864-B2 | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor | HOUSE EAR INSTITUTE (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150038464-A1 | METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2015-02-05 | — | — | US | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-1404864-A4 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | UNIV ROCKEFELLER (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007029063-A2 | TREATMENT AND/OR PREVENTION OF PERVASIVE DEVELOPMENTAL DISORDERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-7129073-B2 | Regulation of neuronal function through metabotropic glutamate receptor signaling pathways | THE ROCKEFELLER UNIVERSITY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20060223158-A1 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-05 | — | — | US | disclosed |
| EP-1404864-A2 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | THE ROCKEFELLER UNIVERSITY (US) | 2004-04-07 | — | — | EP | disclosed |
| WO-2002102768-A2 | REGULATION OF NEURONAL FUNCTION THROUGH METABOTROPIC GLUTAMATE RECEPTOR SIGNALING PATHWAYS | THE ROCKEFELLER UNIVERSITY (US) | 2002-12-27 | — | — | WO | disclosed |
| US-6197820-B1 | METABOTROPIC GLUTAMATE RECEPTOR AGONIST/ANTAGONIST (S)-4-CARBOXYPHENYLGLYCINE (S-4CPG), POTENTLY AND SELECTIVELY INHIBITED GLUTAMATE RELEASE FROM GLIOMA CELLS AND THEREBY PREVENTED NEUROTOXICITY, INHIBIT RELEASE OF TOXIC LEVELS OF | UAB RESEARCH FOUNDATION | 2001-03-06 | — | — | US | disclosed |
| WO-2000062771-A1 | USES OF PHENYLGLYCINE DERIVATIVES | THE UAB RESEARCH FOUNDATION (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038464-A1 | METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION | GRM5, GRM1, GRIK5 | HTT 2316/4885ALDH1A1 445/4885HCAR3 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.